Czech National Bank Raises Holdings in Abbott Laboratories $ABT

Czech National Bank increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 495,786 shares of the healthcare product maker’s stock after buying an additional 22,212 shares during the period. Czech National Bank’s holdings in Abbott Laboratories were worth $44,988,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of ABT. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the fourth quarter worth about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on ABT. Barclays decreased their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Sanford C. Bernstein dropped their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Argus reduced their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Leerink Partners dropped their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $118.17.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $107.86 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a market capitalization of $186.63 billion, a P/E ratio of 34.90, a PEG ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The stock has a 50 day moving average price of $95.06 and a two-hundred day moving average price of $99.97.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the business posted $1.26 EPS. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.